HDIM
SRNE

Hanson & Doremus Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Hanson & Doremus Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,000
Closed -$1K – 474
2023
Q1 		$1K Buy
+3,000
New +$2.69K ﹤0.01% 455

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Hanson & Doremus Investment Management's SRNE Position: Q2 2023 in Review

Hanson & Doremus Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 3,000 shares — an estimated $1K sold.

Hanson & Doremus Investment Management first reported a position in SRNE in Q1 2023 and held it in 1 quarter. The position peaked at $1K in Q1 2023. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Hanson & Doremus Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 3,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $1K.
  • Hanson & Doremus Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Hanson & Doremus Investment Management's Sorrento Therapeutics, Inc. position peaked at $1K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2023, filed 18 Jul 2023.